http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2726914-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f2d76558adf7dba77901370e0d95bfa |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24222 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24234 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
| filingDate | 2009-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96b3a01c20f7a9865d77ad1fdf04d91c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_449c2dd07c899ecdc472f4dd2dcc8516 |
| publicationDate | 2009-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2726914-A1 |
| titleOfInvention | A vaccine for the prevention and therapy of hcv infections |
| abstract | The present invention relates to CD81-binding peptides of the hepatitis virus C(HCV)E2 glycoprotein, which are devoid of or mutated within the amino-terminal 27 amino acids of the mature E2 envelope glycoprotein, or variant thereof which retains the ability to bind to CD81. Furthermore, the present invention provides polypeptides comprising said CD81-binding peptide, polynucleotides encoding the CD81-binding peptide, and expression cassettes and vectors comprising the polynucleotide of the invention. Moreover, the present invention relates to compositions comprising the CD81-binding peptide, the polynucleotide encoding the CD81-binding peptide, the expression cassette, or the vector, and an adjuvant. Furthermore, the present invention provides a pharmaceutical composition comprising the CD81-binding peptide, the polynucleotide, the expression cassette, the vector, or the composition of the invention, and a pharmaceutically acceptable excipient, carrier, or diluent. Moreover, the present invention provides the CD81-binding peptide, the polynucleotide, the expression cassette, the vector, the composition, or the pharmaceutical composition of the invention for induction of an immune response, preferably a broad specificity immune response, against HCV in a mammal, and methods for inducing a therapeutic and/or prophylactic immune response against HCV in a mammal, preferably against HCV of various genotypes. |
| priorityDate | 2008-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 660.